CD2665 (0.6 mg/kg; Subcutaneous injection; daily, for 22 days) completely inhibits the overexpression of RARβ mRNA in the brain of alcohol treated mice[2].
CD2665 is a selective retinoid antagonist and elicits the expected maturation delay and growth plate expansion[3].
| Animal Model: | Mice submitted to 10 months of ethanol consumption[2]. |
| Dosage: | 0.6 mg/kg |
| Administration: | Subcutaneous injection; daily, for 22 days. |
| Result: | Decreased brain RARβ mRNA levels (50% relative to control), without any change in RXR β/γ mRNA levels.
|
| Animal Model: | Male and female mice (3 weeks)[3]. |
| Dosage: | 1.6 mg/kg |
| Administration: | Oral gavage/intragastric; daily, for 31 days. |
| Result: | Growth plate closure had largely been prevented in LDE225/antagonist co-treated mice compared with those receiving LDE225 only. |
![4-[7-(1-adamantyl)-6-(2-methoxyethoxymethoxy)naphthalen-2-yl]benzoic a cid Structure](/CAS/GIF/170355-78-9.gif)
